dorsaVi Advances 22-nm RRAM Tech with ITRI Collaboration and Advisory Board

Strategic Leap to 22-nm RRAM with ITRI Partnership

dorsaVi (ASX:DVL) has taken a decisive step in semiconductor innovation by teaming up with Taiwan’s Industrial Technology Research Institute (ITRI) and Singapore’s Nanyang Technological University (NTU) to advance its proprietary Resistive Random Access Memory (RRAM) platform to the 22-nanometre technology node. This multi-year collaboration aims to push the boundaries of memory density, speed, and power efficiency, unlocking capabilities critical for neuromorphic and in-memory computing applications.

The 22-nm node is a pivotal upgrade from legacy 180-nm and 40-nm processes, enabling significantly higher memory density and faster access speeds with lower power consumption. This development is tailored to meet the rising demands of robotics, wearables, industrial automation, and medical devices that require ultra-low power and low-latency computing solutions not achievable with off-the-shelf silicon. The program leverages dorsaVi’s system-level IP combined with NTU and ITRI’s device and circuit design expertise, aiming for a scalable path to mass production through a world-class foundry service.

Technical Advisory Board Bolsters Ultra-Edge Intelligence Vision

To steer this ambitious technological transition, dorsaVi has established a Technical Advisory Board comprising industry veterans and academic leaders. Robotics expert Roger Peniche brings over 25 years of experience in industrial automation, ensuring the company’s technologies align with real-world deployment and regulatory requirements. Professor Wen Siang Lew, an RRAM and nanoelectronics authority, provides deep insight into device physics and reliability essential for advanced-node scaling. Meanwhile, Professor Shahar Kvatinsky, a global leader in neuromorphic and in-memory processing, guides the integration of dorsaVi’s RRAM into intelligent computing fabrics.

This advisory board underpins dorsaVi’s “Intelligence at the Ultra Edge” strategy, which aims to embed sensing, memory, and computation directly into compact silicon for robotics, wearables, and autonomous systems. The goal is to achieve microsecond-class response times, nanojoule-class energy consumption, and adaptive in-memory learning capabilities.

On-Sensor Intelligence and Neuromorphic IP Acquisition

Complementing hardware advancements, dorsaVi has rolled out its Sensor V6.5 firmware upgrade, which introduces on-sensor processing capabilities to its existing FDA- and TGA-cleared wearable sensor platform. This upgrade reduces latency by performing selected analytics directly within the sensor, laying the groundwork for future neuromorphic compute integration without requiring hardware replacement. The V6.5 framework is designed to accommodate dorsaVi’s neuromorphic IP, acquired recently from the Technion in Israel, which strengthens the company’s portfolio in processing-in-memory architectures.

These moves position dorsaVi to deliver ultra-low power, real-time AI-driven decisions locally at the point of sensing, reducing dependence on cloud connectivity and enabling applications in latency- and power-constrained environments. The acquisition also opens doors for collaboration with Israeli commercial partners and venture capital firms, tapping into a vibrant semiconductor and AI hardware ecosystem.

Commercial Traction in Elite Sport and Clinical Research

dorsaVi’s technology is gaining commercial momentum beyond its RRAM developments. The company has secured significant contracts, including an 8-month collaboration with Dr Chirag Patel, a leading US foot and ankle physician with ties to ESPN and elite sports leagues, to develop advanced lower-limb analytics. This partnership not only brings revenue but also enhances dorsaVi’s credibility in sports medicine and military applications.

In Europe, dorsaVi’s sensors have been selected for the landmark SEROMA project, aimed at establishing objective outcome measures for Axial Spondyloarthritis, a chronic inflammatory condition. This clinical endorsement, involving top rheumatologists and pharmaceutical companies, validates dorsaVi’s sensor technology in a critical healthcare domain.

Meanwhile, the Select Medical physical therapy network in the US continues to expand, integrating dorsaVi’s ViMove+ platform across more than 100 sites, reflecting growing adoption in rehabilitation and occupational health markets.

Financial Position and Operational Outlook

As of 31 March 2026, dorsaVi held $3.1 million in cash. The company recorded $220,000 in cash receipts from customers during the quarter, with operating cash outflows of approximately $1.9 million, including one-off payments related to licensing and chip manufacturing. Going forward, dorsaVi expects operating expenses to normalise to around $700,000 to $800,000 per quarter, maintaining roughly a 12-month runway. This financial posture underscores the importance of advancing commercial partnerships and managing development milestones carefully.

dorsaVi’s progress with the 22-nm RRAM program and sensor intelligence upgrades builds on its recent firmware upgrade rollout and aligns with its broader Ultra-Edge Modular Design program aimed at manufacturable hardware platforms for robotics and AI. These developments collectively position dorsaVi at the nexus of next-generation memory technology and real-world AI applications.